Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.30 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6641039 | 1.00 | MEN1 (0.38) | MEN1KMT2AHTR6KDM4EALDH1A1 | |
| SCHEMBL14628579 | 1.00 | MEN1 (0.38) | MEN1KMT2AHTR6KDM4EALDH1A1 | |
| SCHEMBL1202752 | 0.97 | MEN1 (0.36) | MEN1KMT2AHTR6KDM4EALDH1A1 | |
| SCHEMBL3420145 | 0.95 | — | — | |
| SCHEMBL9388849 | 0.92 | HTR6 (0.40) | MEN1KMT2AHTR6KDM4EALDH1A1 | |
| SCHEMBL9632289 | 0.92 | KDM4E (0.38) | MEN1KMT2AHTR6KDM4EALDH1A1 | |
| SCHEMBL22628194 | 0.92 | HTR6 (0.40) | MEN1KMT2AHTR6KDM4EALDH1A1 | |
| SCHEMBL1181468 | 0.92 | HTR6 (0.40) | MEN1KMT2AHTR6KDM4EALDH1A1 | |
| SCHEMBL5241137 | 0.90 | HTR6 (0.39) | MEN1KMT2AHTR6KDM4EALDH1A1 | |
| SCHEMBL6817248 | 0.90 | HTR6 (0.39) | MEN1KMT2AHTR6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326846-A4 | PROCESS FOR PREPARATION OF INTEGRIN RECEPTOR ANTAGONIST INTERMEDIATES | MERCK & CO INC (US) | 2004-04-21 | — | — | EP | claimed |
| US-20040030134-A1 | Process for preparation of integrin receptor antagonist intermediates | MERCK & CO., INC. | 2004-02-12 | — | — | US | claimed |
| EP-1326846-A1 | PROCESS FOR PREPARATION OF INTEGRIN RECEPTOR ANTAGONIST INTERMEDIATES | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| CN-1092696-C | Chemical Mechanical Polishing Composition | CHANGXING CHEMICAL IND CO LTD (CN) | 2002-10-16 | — | — | CN | claimed |
| WO-2002028840-A1 | PROCESS FOR PREPARATION OF INTEGRIN RECEPTOR ANTAGONIST INTERMEDIATES | MERCK & CO., INC. (US) | 2002-04-11 | — | — | WO | claimed |
| US-11814447-B2 | Peptide ligands for binding to EphA2 | Bicyclerd Limited (GB) | 2023-11-14 | — | — | US | disclosed |
| EP-3083646-A1 | PHOSPHINYL FORMAMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | Chevron Phillips Chemical Company LP (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015094207-A1 | PHOSPHINYL FORMAMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2858750-A1 | PHOSPHINYL GUANIDINE COMPOUNDS, METAL SALT COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | Chevron Phillips Chemical Company LP (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2797862-A1 | OLEFIN OLIGOMERIZATION METHODS | Chevron Phillips Chemical Company LP (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2791091-A1 | PREPARATION OF TRANSITION METAL CARBOXYLATES | Chevron Phillips Chemical Company LP (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2790828-A1 | PREPARATION OF AN OLEFIN OLIGOMERIZATION CATALYST | Chevron Phillips Chemical Company LP (US) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013089963-A1 | PREPARATION OF TRANSITION METAL CARBOXYLATES | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2013-06-20 | — | — | WO | disclosed |
| EP-2519532-A1 | PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | Chevron Phillips Chemical Company LP (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2012092415-A1 | OLEFIN OLIGOMERIZATION CATALYSTS AND METHODS OF MAKING AND USING SAME | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2012-07-05 | — | — | WO | disclosed |
| EP-2443160-A1 | OLIGOMERIZATION OF ALPHA OLEFINS USING METALLOCENE-SSA CATALYST SYSTEMS AND USE OF THE RESULTANT POLYALPHAOLEFINS TO PREPARE LUBRICANT BLENDS | Chevron Phillips Chemical Company LP (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2011082192-A1 | PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2010147993-A1 | OLIGOMERIZATION OF ALPHA OLEFINS USING METALLOCENE-SSA CATALYST SYSTEMS AND USE OF THE RESULTANT POLYALPHAOLEFINS TO PREPARE LUBRICANT BLENDS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20040030134-A1 | Process for preparation of integrin receptor antagonist intermediates | MERCK & CO., INC. | 2004-02-12 | — | — | US | disclosed |
| CN-1092696-C | Chemical Mechanical Polishing Composition | CHANGXING CHEMICAL IND CO LTD (CN) | 2002-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030134-A1 | Process for preparation of integrin receptor antagonist intermediates | ITGB3, ITGAL, ITGB1 | MEN1 4216/4885KMT2A 3821/4885HTR6 976/4885 |
| US-11814447-B2 | Peptide ligands for binding to EphA2 | EPHA2, CD2BP2, LNPEP | MEN1 4602/4885KMT2A 3286/4885HTR6 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.